nodes	percent_of_prediction	percent_of_DWPC	metapath
Iloperidone—Gefitinib—Erlotinib—pancreatic cancer	0.5	1	CrCrCtD
Iloperidone—SIGMAR1—Tamoxifen—pancreatic cancer	0.065	0.188	CbGbCtD
Iloperidone—CYP2E1—Dacarbazine—pancreatic cancer	0.0224	0.0649	CbGbCtD
Iloperidone—CYP3A7-CYP3A51P—Tamoxifen—pancreatic cancer	0.0184	0.0535	CbGbCtD
Iloperidone—CYP3A7—Tamoxifen—pancreatic cancer	0.0184	0.0535	CbGbCtD
Iloperidone—CYP2E1—Tamoxifen—pancreatic cancer	0.0178	0.0516	CbGbCtD
Iloperidone—CYP3A7—Irinotecan—pancreatic cancer	0.0142	0.0411	CbGbCtD
Iloperidone—CYP3A7-CYP3A51P—Irinotecan—pancreatic cancer	0.0142	0.0411	CbGbCtD
Iloperidone—CYP3A5—Tamoxifen—pancreatic cancer	0.0138	0.0401	CbGbCtD
Iloperidone—CYP1A2—Dacarbazine—pancreatic cancer	0.0129	0.0375	CbGbCtD
Iloperidone—CYP3A5—Erlotinib—pancreatic cancer	0.0118	0.0341	CbGbCtD
Iloperidone—CYP3A5—Irinotecan—pancreatic cancer	0.0106	0.0308	CbGbCtD
Iloperidone—CYP3A7-CYP3A51P—Docetaxel—pancreatic cancer	0.0104	0.0301	CbGbCtD
Iloperidone—CYP3A7—Docetaxel—pancreatic cancer	0.0104	0.0301	CbGbCtD
Iloperidone—CYP3A7-CYP3A51P—Sunitinib—pancreatic cancer	0.0103	0.03	CbGbCtD
Iloperidone—CYP3A7—Sunitinib—pancreatic cancer	0.0103	0.03	CbGbCtD
Iloperidone—CYP1A2—Tamoxifen—pancreatic cancer	0.0103	0.0299	CbGbCtD
Iloperidone—CYP1A2—Erlotinib—pancreatic cancer	0.00876	0.0254	CbGbCtD
Iloperidone—CYP2D6—Tamoxifen—pancreatic cancer	0.00849	0.0246	CbGbCtD
Iloperidone—CYP3A5—Docetaxel—pancreatic cancer	0.00779	0.0226	CbGbCtD
Iloperidone—CYP3A5—Sunitinib—pancreatic cancer	0.00775	0.0225	CbGbCtD
Iloperidone—CYP1A2—Fluorouracil—pancreatic cancer	0.00759	0.022	CbGbCtD
Iloperidone—CYP2D6—Erlotinib—pancreatic cancer	0.00722	0.0209	CbGbCtD
Iloperidone—CYP3A4—Tamoxifen—pancreatic cancer	0.0054	0.0156	CbGbCtD
Iloperidone—CYP3A4—Erlotinib—pancreatic cancer	0.00459	0.0133	CbGbCtD
Iloperidone—CYP3A4—Irinotecan—pancreatic cancer	0.00414	0.012	CbGbCtD
Iloperidone—CYP2D6—Doxorubicin—pancreatic cancer	0.00356	0.0103	CbGbCtD
Iloperidone—CYP3A4—Docetaxel—pancreatic cancer	0.00304	0.0088	CbGbCtD
Iloperidone—CYP3A4—Sunitinib—pancreatic cancer	0.00302	0.00876	CbGbCtD
Iloperidone—CYP3A4—Doxorubicin—pancreatic cancer	0.00226	0.00656	CbGbCtD
Iloperidone—HTR7—enteric nervous system—pancreatic cancer	0.00219	0.408	CbGeAlD
Iloperidone—HTR2A—enteric nervous system—pancreatic cancer	0.00136	0.254	CbGeAlD
Iloperidone—Gefitinib—EGFR—pancreatic cancer	0.000332	1	CrCbGaD
Iloperidone—SIGMAR1—islet of Langerhans—pancreatic cancer	0.000245	0.0456	CbGeAlD
Iloperidone—SIGMAR1—pancreas—pancreatic cancer	0.000172	0.032	CbGeAlD
Iloperidone—CYP3A5—islet of Langerhans—pancreatic cancer	0.000161	0.03	CbGeAlD
Iloperidone—ADRA2A—islet of Langerhans—pancreatic cancer	0.000153	0.0286	CbGeAlD
Iloperidone—Mouth ulceration—Doxorubicin—pancreatic cancer	0.000148	0.00173	CcSEcCtD
Iloperidone—Paraesthesia—Sunitinib—pancreatic cancer	0.000147	0.00173	CcSEcCtD
Iloperidone—Anaemia—Fluorouracil—pancreatic cancer	0.000147	0.00172	CcSEcCtD
Iloperidone—Dyspnoea—Sunitinib—pancreatic cancer	0.000146	0.00172	CcSEcCtD
Iloperidone—Leukopenia—Gemcitabine—pancreatic cancer	0.000145	0.00169	CcSEcCtD
Iloperidone—Stomatitis—Docetaxel—pancreatic cancer	0.000143	0.00167	CcSEcCtD
Iloperidone—Conjunctivitis—Docetaxel—pancreatic cancer	0.000143	0.00167	CcSEcCtD
Iloperidone—Leukopenia—Fluorouracil—pancreatic cancer	0.000142	0.00167	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.000142	0.00166	CcSEcCtD
Iloperidone—Fatigue—Sunitinib—pancreatic cancer	0.000142	0.00166	CcSEcCtD
Iloperidone—Renal failure acute—Epirubicin—pancreatic cancer	0.000139	0.00163	CcSEcCtD
Iloperidone—Hepatobiliary disease—Docetaxel—pancreatic cancer	0.000139	0.00163	CcSEcCtD
Iloperidone—Epistaxis—Docetaxel—pancreatic cancer	0.000138	0.00162	CcSEcCtD
Iloperidone—Asthenia—Tamoxifen—pancreatic cancer	0.000138	0.00161	CcSEcCtD
Iloperidone—Myalgia—Gemcitabine—pancreatic cancer	0.000137	0.00161	CcSEcCtD
Iloperidone—Arthralgia—Gemcitabine—pancreatic cancer	0.000137	0.00161	CcSEcCtD
Iloperidone—Increased appetite—Epirubicin—pancreatic cancer	0.000137	0.0016	CcSEcCtD
Iloperidone—Confusional state—Irinotecan—pancreatic cancer	0.000136	0.0016	CcSEcCtD
Iloperidone—Asthenia—Erlotinib—pancreatic cancer	0.000136	0.0016	CcSEcCtD
Iloperidone—Oedema—Irinotecan—pancreatic cancer	0.000135	0.00159	CcSEcCtD
Iloperidone—Myalgia—Fluorouracil—pancreatic cancer	0.000135	0.00158	CcSEcCtD
Iloperidone—ADRA2C—pancreas—pancreatic cancer	0.000135	0.0252	CbGeAlD
Iloperidone—Infection—Irinotecan—pancreatic cancer	0.000134	0.00157	CcSEcCtD
Iloperidone—Nervous system disorder—Irinotecan—pancreatic cancer	0.000133	0.00155	CcSEcCtD
Iloperidone—Oedema—Gemcitabine—pancreatic cancer	0.000132	0.00154	CcSEcCtD
Iloperidone—Cardiac failure—Epirubicin—pancreatic cancer	0.000132	0.00154	CcSEcCtD
Iloperidone—Diarrhoea—Tamoxifen—pancreatic cancer	0.000131	0.00154	CcSEcCtD
Iloperidone—Lethargy—Epirubicin—pancreatic cancer	0.000131	0.00153	CcSEcCtD
Iloperidone—Infection—Gemcitabine—pancreatic cancer	0.000131	0.00153	CcSEcCtD
Iloperidone—Confusional state—Fluorouracil—pancreatic cancer	0.000131	0.00153	CcSEcCtD
Iloperidone—Urinary tract disorder—Docetaxel—pancreatic cancer	0.00013	0.00152	CcSEcCtD
Iloperidone—Body temperature increased—Sunitinib—pancreatic cancer	0.00013	0.00152	CcSEcCtD
Iloperidone—Diarrhoea—Erlotinib—pancreatic cancer	0.00013	0.00152	CcSEcCtD
Iloperidone—Oedema—Fluorouracil—pancreatic cancer	0.00013	0.00152	CcSEcCtD
Iloperidone—Connective tissue disorder—Docetaxel—pancreatic cancer	0.000129	0.00152	CcSEcCtD
Iloperidone—Nervous system disorder—Gemcitabine—pancreatic cancer	0.000129	0.00151	CcSEcCtD
Iloperidone—Urethral disorder—Docetaxel—pancreatic cancer	0.000129	0.00151	CcSEcCtD
Iloperidone—Infection—Fluorouracil—pancreatic cancer	0.000129	0.00151	CcSEcCtD
Iloperidone—Renal failure acute—Doxorubicin—pancreatic cancer	0.000129	0.00151	CcSEcCtD
Iloperidone—Nervous system disorder—Fluorouracil—pancreatic cancer	0.000127	0.00149	CcSEcCtD
Iloperidone—Dizziness—Tamoxifen—pancreatic cancer	0.000127	0.00149	CcSEcCtD
Iloperidone—Tachycardia—Fluorouracil—pancreatic cancer	0.000126	0.00148	CcSEcCtD
Iloperidone—Hypotension—Irinotecan—pancreatic cancer	0.000126	0.00148	CcSEcCtD
Iloperidone—Increased appetite—Doxorubicin—pancreatic cancer	0.000126	0.00148	CcSEcCtD
Iloperidone—Affect lability—Epirubicin—pancreatic cancer	0.000126	0.00148	CcSEcCtD
Iloperidone—HTR7—digestive system—pancreatic cancer	0.000125	0.0234	CbGeAlD
Iloperidone—Dizziness—Erlotinib—pancreatic cancer	0.000125	0.00147	CcSEcCtD
Iloperidone—Hypotension—Gemcitabine—pancreatic cancer	0.000123	0.00144	CcSEcCtD
Iloperidone—Eye disorder—Docetaxel—pancreatic cancer	0.000123	0.00144	CcSEcCtD
Iloperidone—Cardiac disorder—Docetaxel—pancreatic cancer	0.000122	0.00143	CcSEcCtD
Iloperidone—Cardiac failure—Doxorubicin—pancreatic cancer	0.000122	0.00143	CcSEcCtD
Iloperidone—Mood swings—Epirubicin—pancreatic cancer	0.000122	0.00142	CcSEcCtD
Iloperidone—Paraesthesia—Irinotecan—pancreatic cancer	0.000121	0.00142	CcSEcCtD
Iloperidone—Lethargy—Doxorubicin—pancreatic cancer	0.000121	0.00142	CcSEcCtD
Iloperidone—Hypotension—Fluorouracil—pancreatic cancer	0.000121	0.00142	CcSEcCtD
Iloperidone—Rash—Tamoxifen—pancreatic cancer	0.000121	0.00142	CcSEcCtD
Iloperidone—Dermatitis—Tamoxifen—pancreatic cancer	0.000121	0.00142	CcSEcCtD
Iloperidone—Dyspnoea—Irinotecan—pancreatic cancer	0.000121	0.00141	CcSEcCtD
Iloperidone—Somnolence—Irinotecan—pancreatic cancer	0.00012	0.00141	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.00012	0.00141	CcSEcCtD
Iloperidone—Rash—Erlotinib—pancreatic cancer	0.00012	0.0014	CcSEcCtD
Iloperidone—Dermatitis—Erlotinib—pancreatic cancer	0.00012	0.0014	CcSEcCtD
Iloperidone—Angiopathy—Docetaxel—pancreatic cancer	0.000119	0.0014	CcSEcCtD
Iloperidone—Dehydration—Epirubicin—pancreatic cancer	0.000119	0.0014	CcSEcCtD
Iloperidone—Mediastinal disorder—Docetaxel—pancreatic cancer	0.000119	0.00139	CcSEcCtD
Iloperidone—Paraesthesia—Gemcitabine—pancreatic cancer	0.000118	0.00139	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.000118	0.00138	CcSEcCtD
Iloperidone—Asthenia—Sunitinib—pancreatic cancer	0.000118	0.00138	CcSEcCtD
Iloperidone—Arrhythmia—Docetaxel—pancreatic cancer	0.000118	0.00138	CcSEcCtD
Iloperidone—Dyspnoea—Gemcitabine—pancreatic cancer	0.000118	0.00138	CcSEcCtD
Iloperidone—Orthostatic hypotension—Epirubicin—pancreatic cancer	0.000117	0.00137	CcSEcCtD
Iloperidone—Somnolence—Gemcitabine—pancreatic cancer	0.000117	0.00137	CcSEcCtD
Iloperidone—Affect lability—Doxorubicin—pancreatic cancer	0.000117	0.00137	CcSEcCtD
Iloperidone—Hypokalaemia—Epirubicin—pancreatic cancer	0.000117	0.00137	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000117	0.00137	CcSEcCtD
Iloperidone—Fatigue—Irinotecan—pancreatic cancer	0.000117	0.00137	CcSEcCtD
Iloperidone—Paraesthesia—Fluorouracil—pancreatic cancer	0.000116	0.00136	CcSEcCtD
Iloperidone—Breast disorder—Epirubicin—pancreatic cancer	0.000116	0.00136	CcSEcCtD
Iloperidone—Dyspnoea—Fluorouracil—pancreatic cancer	0.000116	0.00135	CcSEcCtD
Iloperidone—Mental disorder—Docetaxel—pancreatic cancer	0.000115	0.00135	CcSEcCtD
Iloperidone—Somnolence—Fluorouracil—pancreatic cancer	0.000115	0.00135	CcSEcCtD
Iloperidone—Nasopharyngitis—Epirubicin—pancreatic cancer	0.000115	0.00134	CcSEcCtD
Iloperidone—Malnutrition—Docetaxel—pancreatic cancer	0.000115	0.00134	CcSEcCtD
Iloperidone—Nausea—Tamoxifen—pancreatic cancer	0.000114	0.00133	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000114	0.00133	CcSEcCtD
Iloperidone—Fatigue—Gemcitabine—pancreatic cancer	0.000114	0.00133	CcSEcCtD
Iloperidone—Gastritis—Epirubicin—pancreatic cancer	0.000114	0.00133	CcSEcCtD
Iloperidone—CYP3A5—pancreas—pancreatic cancer	0.000113	0.0211	CbGeAlD
Iloperidone—Nausea—Erlotinib—pancreatic cancer	0.000113	0.00132	CcSEcCtD
Iloperidone—Mood swings—Doxorubicin—pancreatic cancer	0.000113	0.00132	CcSEcCtD
Iloperidone—Diarrhoea—Sunitinib—pancreatic cancer	0.000112	0.00132	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000112	0.00131	CcSEcCtD
Iloperidone—Feeling abnormal—Irinotecan—pancreatic cancer	0.000111	0.00131	CcSEcCtD
Iloperidone—Asthma—Epirubicin—pancreatic cancer	0.000111	0.0013	CcSEcCtD
Iloperidone—Dehydration—Doxorubicin—pancreatic cancer	0.00011	0.00129	CcSEcCtD
Iloperidone—Muscle spasms—Docetaxel—pancreatic cancer	0.00011	0.00129	CcSEcCtD
Iloperidone—Dizziness—Sunitinib—pancreatic cancer	0.000109	0.00127	CcSEcCtD
Iloperidone—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000109	0.00127	CcSEcCtD
Iloperidone—Orthostatic hypotension—Doxorubicin—pancreatic cancer	0.000108	0.00127	CcSEcCtD
Iloperidone—Hypokalaemia—Doxorubicin—pancreatic cancer	0.000108	0.00127	CcSEcCtD
Iloperidone—ADRA2A—pancreas—pancreatic cancer	0.000108	0.0201	CbGeAlD
Iloperidone—Breast disorder—Doxorubicin—pancreatic cancer	0.000107	0.00126	CcSEcCtD
Iloperidone—Body temperature increased—Irinotecan—pancreatic cancer	0.000107	0.00125	CcSEcCtD
Iloperidone—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000107	0.00125	CcSEcCtD
Iloperidone—Nasopharyngitis—Doxorubicin—pancreatic cancer	0.000106	0.00124	CcSEcCtD
Iloperidone—Anaemia—Docetaxel—pancreatic cancer	0.000106	0.00124	CcSEcCtD
Iloperidone—Gastritis—Doxorubicin—pancreatic cancer	0.000105	0.00123	CcSEcCtD
Iloperidone—Body temperature increased—Gemcitabine—pancreatic cancer	0.000104	0.00122	CcSEcCtD
Iloperidone—Dysuria—Epirubicin—pancreatic cancer	0.000104	0.00122	CcSEcCtD
Iloperidone—Rash—Sunitinib—pancreatic cancer	0.000104	0.00121	CcSEcCtD
Iloperidone—Dermatitis—Sunitinib—pancreatic cancer	0.000103	0.00121	CcSEcCtD
Iloperidone—Upper respiratory tract infection—Epirubicin—pancreatic cancer	0.000103	0.00121	CcSEcCtD
Iloperidone—Asthma—Doxorubicin—pancreatic cancer	0.000103	0.0012	CcSEcCtD
Iloperidone—Leukopenia—Docetaxel—pancreatic cancer	0.000103	0.0012	CcSEcCtD
Iloperidone—Pollakiuria—Epirubicin—pancreatic cancer	0.000102	0.0012	CcSEcCtD
Iloperidone—Body temperature increased—Fluorouracil—pancreatic cancer	0.000102	0.0012	CcSEcCtD
Iloperidone—Palpitations—Docetaxel—pancreatic cancer	0.000101	0.00119	CcSEcCtD
Iloperidone—Weight increased—Epirubicin—pancreatic cancer	0.000101	0.00118	CcSEcCtD
Iloperidone—Weight decreased—Epirubicin—pancreatic cancer	0.0001	0.00118	CcSEcCtD
Iloperidone—CYP1A2—digestive system—pancreatic cancer	0.0001	0.0187	CbGeAlD
Iloperidone—Arthralgia—Docetaxel—pancreatic cancer	9.76e-05	0.00114	CcSEcCtD
Iloperidone—Myalgia—Docetaxel—pancreatic cancer	9.76e-05	0.00114	CcSEcCtD
Iloperidone—Nausea—Sunitinib—pancreatic cancer	9.76e-05	0.00114	CcSEcCtD
Iloperidone—Asthenia—Irinotecan—pancreatic cancer	9.71e-05	0.00114	CcSEcCtD
Iloperidone—CYP3A5—digestive system—pancreatic cancer	9.65e-05	0.018	CbGeAlD
Iloperidone—Stomatitis—Epirubicin—pancreatic cancer	9.64e-05	0.00113	CcSEcCtD
Iloperidone—Conjunctivitis—Epirubicin—pancreatic cancer	9.61e-05	0.00113	CcSEcCtD
Iloperidone—Dysuria—Doxorubicin—pancreatic cancer	9.6e-05	0.00112	CcSEcCtD
Iloperidone—Dry mouth—Docetaxel—pancreatic cancer	9.54e-05	0.00112	CcSEcCtD
Iloperidone—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	9.54e-05	0.00112	CcSEcCtD
Iloperidone—Pollakiuria—Doxorubicin—pancreatic cancer	9.48e-05	0.00111	CcSEcCtD
Iloperidone—Asthenia—Gemcitabine—pancreatic cancer	9.46e-05	0.00111	CcSEcCtD
Iloperidone—Confusional state—Docetaxel—pancreatic cancer	9.43e-05	0.0011	CcSEcCtD
Iloperidone—HRH1—digestive system—pancreatic cancer	9.37e-05	0.0175	CbGeAlD
Iloperidone—Hepatobiliary disease—Epirubicin—pancreatic cancer	9.35e-05	0.0011	CcSEcCtD
Iloperidone—Oedema—Docetaxel—pancreatic cancer	9.35e-05	0.0011	CcSEcCtD
Iloperidone—Weight increased—Doxorubicin—pancreatic cancer	9.34e-05	0.00109	CcSEcCtD
Iloperidone—Epistaxis—Epirubicin—pancreatic cancer	9.33e-05	0.00109	CcSEcCtD
Iloperidone—Infection—Docetaxel—pancreatic cancer	9.29e-05	0.00109	CcSEcCtD
Iloperidone—Weight decreased—Doxorubicin—pancreatic cancer	9.29e-05	0.00109	CcSEcCtD
Iloperidone—Diarrhoea—Irinotecan—pancreatic cancer	9.26e-05	0.00108	CcSEcCtD
Iloperidone—Nervous system disorder—Docetaxel—pancreatic cancer	9.17e-05	0.00107	CcSEcCtD
Iloperidone—Tachycardia—Docetaxel—pancreatic cancer	9.13e-05	0.00107	CcSEcCtD
Iloperidone—Diarrhoea—Gemcitabine—pancreatic cancer	9.02e-05	0.00106	CcSEcCtD
Iloperidone—CYP2E1—digestive system—pancreatic cancer	9e-05	0.0168	CbGeAlD
Iloperidone—Dizziness—Irinotecan—pancreatic cancer	8.95e-05	0.00105	CcSEcCtD
Iloperidone—Stomatitis—Doxorubicin—pancreatic cancer	8.92e-05	0.00105	CcSEcCtD
Iloperidone—Conjunctivitis—Doxorubicin—pancreatic cancer	8.9e-05	0.00104	CcSEcCtD
Iloperidone—Diarrhoea—Fluorouracil—pancreatic cancer	8.87e-05	0.00104	CcSEcCtD
Iloperidone—Urinary tract disorder—Epirubicin—pancreatic cancer	8.77e-05	0.00103	CcSEcCtD
Iloperidone—Hypotension—Docetaxel—pancreatic cancer	8.74e-05	0.00102	CcSEcCtD
Iloperidone—Connective tissue disorder—Epirubicin—pancreatic cancer	8.73e-05	0.00102	CcSEcCtD
Iloperidone—Urethral disorder—Epirubicin—pancreatic cancer	8.7e-05	0.00102	CcSEcCtD
Iloperidone—Hepatobiliary disease—Doxorubicin—pancreatic cancer	8.66e-05	0.00101	CcSEcCtD
Iloperidone—Epistaxis—Doxorubicin—pancreatic cancer	8.63e-05	0.00101	CcSEcCtD
Iloperidone—Dizziness—Fluorouracil—pancreatic cancer	8.57e-05	0.001	CcSEcCtD
Iloperidone—Rash—Irinotecan—pancreatic cancer	8.53e-05	0.001	CcSEcCtD
Iloperidone—Dermatitis—Irinotecan—pancreatic cancer	8.52e-05	0.000999	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	8.52e-05	0.000998	CcSEcCtD
Iloperidone—Paraesthesia—Docetaxel—pancreatic cancer	8.4e-05	0.000984	CcSEcCtD
Iloperidone—Dyspnoea—Docetaxel—pancreatic cancer	8.34e-05	0.000977	CcSEcCtD
Iloperidone—Somnolence—Docetaxel—pancreatic cancer	8.31e-05	0.000974	CcSEcCtD
Iloperidone—Rash—Gemcitabine—pancreatic cancer	8.31e-05	0.000974	CcSEcCtD
Iloperidone—Dermatitis—Gemcitabine—pancreatic cancer	8.3e-05	0.000973	CcSEcCtD
Iloperidone—Eye disorder—Epirubicin—pancreatic cancer	8.3e-05	0.000972	CcSEcCtD
Iloperidone—Tinnitus—Epirubicin—pancreatic cancer	8.28e-05	0.00097	CcSEcCtD
Iloperidone—Cardiac disorder—Epirubicin—pancreatic cancer	8.24e-05	0.000966	CcSEcCtD
Iloperidone—Rash—Fluorouracil—pancreatic cancer	8.17e-05	0.000957	CcSEcCtD
Iloperidone—Dermatitis—Fluorouracil—pancreatic cancer	8.16e-05	0.000956	CcSEcCtD
Iloperidone—Urinary tract disorder—Doxorubicin—pancreatic cancer	8.11e-05	0.000951	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Docetaxel—pancreatic cancer	8.07e-05	0.000946	CcSEcCtD
Iloperidone—Connective tissue disorder—Doxorubicin—pancreatic cancer	8.07e-05	0.000946	CcSEcCtD
Iloperidone—Fatigue—Docetaxel—pancreatic cancer	8.06e-05	0.000945	CcSEcCtD
Iloperidone—Angiopathy—Epirubicin—pancreatic cancer	8.06e-05	0.000944	CcSEcCtD
Iloperidone—Urethral disorder—Doxorubicin—pancreatic cancer	8.05e-05	0.000944	CcSEcCtD
Iloperidone—Nausea—Irinotecan—pancreatic cancer	8.04e-05	0.000942	CcSEcCtD
Iloperidone—Mediastinal disorder—Epirubicin—pancreatic cancer	8e-05	0.000938	CcSEcCtD
Iloperidone—Arrhythmia—Epirubicin—pancreatic cancer	7.93e-05	0.000929	CcSEcCtD
Iloperidone—Nausea—Gemcitabine—pancreatic cancer	7.83e-05	0.000917	CcSEcCtD
Iloperidone—HTR2A—digestive system—pancreatic cancer	7.83e-05	0.0146	CbGeAlD
Iloperidone—Mental disorder—Epirubicin—pancreatic cancer	7.78e-05	0.000912	CcSEcCtD
Iloperidone—Malnutrition—Epirubicin—pancreatic cancer	7.73e-05	0.000906	CcSEcCtD
Iloperidone—Feeling abnormal—Docetaxel—pancreatic cancer	7.71e-05	0.000903	CcSEcCtD
Iloperidone—Nausea—Fluorouracil—pancreatic cancer	7.7e-05	0.000902	CcSEcCtD
Iloperidone—Eye disorder—Doxorubicin—pancreatic cancer	7.68e-05	0.0009	CcSEcCtD
Iloperidone—Tinnitus—Doxorubicin—pancreatic cancer	7.66e-05	0.000898	CcSEcCtD
Iloperidone—Cardiac disorder—Doxorubicin—pancreatic cancer	7.63e-05	0.000893	CcSEcCtD
Iloperidone—Angiopathy—Doxorubicin—pancreatic cancer	7.45e-05	0.000873	CcSEcCtD
Iloperidone—Muscle spasms—Epirubicin—pancreatic cancer	7.43e-05	0.000871	CcSEcCtD
Iloperidone—Mediastinal disorder—Doxorubicin—pancreatic cancer	7.4e-05	0.000868	CcSEcCtD
Iloperidone—Body temperature increased—Docetaxel—pancreatic cancer	7.39e-05	0.000866	CcSEcCtD
Iloperidone—Arrhythmia—Doxorubicin—pancreatic cancer	7.34e-05	0.00086	CcSEcCtD
Iloperidone—Vision blurred—Epirubicin—pancreatic cancer	7.28e-05	0.000854	CcSEcCtD
Iloperidone—CYP3A4—digestive system—pancreatic cancer	7.24e-05	0.0135	CbGeAlD
Iloperidone—Mental disorder—Doxorubicin—pancreatic cancer	7.2e-05	0.000843	CcSEcCtD
Iloperidone—Malnutrition—Doxorubicin—pancreatic cancer	7.15e-05	0.000838	CcSEcCtD
Iloperidone—Anaemia—Epirubicin—pancreatic cancer	7.14e-05	0.000837	CcSEcCtD
Iloperidone—CYP2D6—digestive system—pancreatic cancer	7.13e-05	0.0133	CbGeAlD
Iloperidone—Agitation—Epirubicin—pancreatic cancer	7.1e-05	0.000832	CcSEcCtD
Iloperidone—Vertigo—Epirubicin—pancreatic cancer	6.94e-05	0.000814	CcSEcCtD
Iloperidone—Leukopenia—Epirubicin—pancreatic cancer	6.92e-05	0.000811	CcSEcCtD
Iloperidone—Muscle spasms—Doxorubicin—pancreatic cancer	6.88e-05	0.000806	CcSEcCtD
Iloperidone—Palpitations—Epirubicin—pancreatic cancer	6.83e-05	0.0008	CcSEcCtD
Iloperidone—Vision blurred—Doxorubicin—pancreatic cancer	6.74e-05	0.00079	CcSEcCtD
Iloperidone—Asthenia—Docetaxel—pancreatic cancer	6.71e-05	0.000786	CcSEcCtD
Iloperidone—Anaemia—Doxorubicin—pancreatic cancer	6.61e-05	0.000775	CcSEcCtD
Iloperidone—Arthralgia—Epirubicin—pancreatic cancer	6.58e-05	0.000771	CcSEcCtD
Iloperidone—Myalgia—Epirubicin—pancreatic cancer	6.58e-05	0.000771	CcSEcCtD
Iloperidone—Agitation—Doxorubicin—pancreatic cancer	6.57e-05	0.00077	CcSEcCtD
Iloperidone—Dry mouth—Epirubicin—pancreatic cancer	6.44e-05	0.000754	CcSEcCtD
Iloperidone—Vertigo—Doxorubicin—pancreatic cancer	6.43e-05	0.000753	CcSEcCtD
Iloperidone—Leukopenia—Doxorubicin—pancreatic cancer	6.4e-05	0.00075	CcSEcCtD
Iloperidone—Diarrhoea—Docetaxel—pancreatic cancer	6.4e-05	0.00075	CcSEcCtD
Iloperidone—Confusional state—Epirubicin—pancreatic cancer	6.36e-05	0.000745	CcSEcCtD
Iloperidone—Palpitations—Doxorubicin—pancreatic cancer	6.32e-05	0.000741	CcSEcCtD
Iloperidone—Oedema—Epirubicin—pancreatic cancer	6.31e-05	0.000739	CcSEcCtD
Iloperidone—Infection—Epirubicin—pancreatic cancer	6.27e-05	0.000734	CcSEcCtD
Iloperidone—Nervous system disorder—Epirubicin—pancreatic cancer	6.19e-05	0.000725	CcSEcCtD
Iloperidone—Dizziness—Docetaxel—pancreatic cancer	6.18e-05	0.000725	CcSEcCtD
Iloperidone—Tachycardia—Epirubicin—pancreatic cancer	6.16e-05	0.000721	CcSEcCtD
Iloperidone—Arthralgia—Doxorubicin—pancreatic cancer	6.09e-05	0.000713	CcSEcCtD
Iloperidone—Myalgia—Doxorubicin—pancreatic cancer	6.09e-05	0.000713	CcSEcCtD
Iloperidone—Dry mouth—Doxorubicin—pancreatic cancer	5.96e-05	0.000698	CcSEcCtD
Iloperidone—Rash—Docetaxel—pancreatic cancer	5.9e-05	0.000691	CcSEcCtD
Iloperidone—Hypotension—Epirubicin—pancreatic cancer	5.89e-05	0.000691	CcSEcCtD
Iloperidone—Dermatitis—Docetaxel—pancreatic cancer	5.89e-05	0.00069	CcSEcCtD
Iloperidone—Confusional state—Doxorubicin—pancreatic cancer	5.89e-05	0.00069	CcSEcCtD
Iloperidone—Oedema—Doxorubicin—pancreatic cancer	5.84e-05	0.000684	CcSEcCtD
Iloperidone—Infection—Doxorubicin—pancreatic cancer	5.8e-05	0.000679	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	5.75e-05	0.000673	CcSEcCtD
Iloperidone—Nervous system disorder—Doxorubicin—pancreatic cancer	5.72e-05	0.000671	CcSEcCtD
Iloperidone—Tachycardia—Doxorubicin—pancreatic cancer	5.7e-05	0.000668	CcSEcCtD
Iloperidone—Paraesthesia—Epirubicin—pancreatic cancer	5.66e-05	0.000664	CcSEcCtD
Iloperidone—Dyspnoea—Epirubicin—pancreatic cancer	5.62e-05	0.000659	CcSEcCtD
Iloperidone—Somnolence—Epirubicin—pancreatic cancer	5.61e-05	0.000657	CcSEcCtD
Iloperidone—Nausea—Docetaxel—pancreatic cancer	5.56e-05	0.000651	CcSEcCtD
Iloperidone—Hypotension—Doxorubicin—pancreatic cancer	5.45e-05	0.000639	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Epirubicin—pancreatic cancer	5.45e-05	0.000638	CcSEcCtD
Iloperidone—Fatigue—Epirubicin—pancreatic cancer	5.44e-05	0.000637	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	5.32e-05	0.000623	CcSEcCtD
Iloperidone—Paraesthesia—Doxorubicin—pancreatic cancer	5.24e-05	0.000614	CcSEcCtD
Iloperidone—Dyspnoea—Doxorubicin—pancreatic cancer	5.2e-05	0.00061	CcSEcCtD
Iloperidone—Feeling abnormal—Epirubicin—pancreatic cancer	5.2e-05	0.000609	CcSEcCtD
Iloperidone—Somnolence—Doxorubicin—pancreatic cancer	5.19e-05	0.000608	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	5.04e-05	0.00059	CcSEcCtD
Iloperidone—Fatigue—Doxorubicin—pancreatic cancer	5.03e-05	0.00059	CcSEcCtD
Iloperidone—Body temperature increased—Epirubicin—pancreatic cancer	4.99e-05	0.000584	CcSEcCtD
Iloperidone—Feeling abnormal—Doxorubicin—pancreatic cancer	4.81e-05	0.000564	CcSEcCtD
Iloperidone—Body temperature increased—Doxorubicin—pancreatic cancer	4.61e-05	0.000541	CcSEcCtD
Iloperidone—Asthenia—Epirubicin—pancreatic cancer	4.53e-05	0.00053	CcSEcCtD
Iloperidone—Diarrhoea—Epirubicin—pancreatic cancer	4.32e-05	0.000506	CcSEcCtD
Iloperidone—Asthenia—Doxorubicin—pancreatic cancer	4.19e-05	0.000491	CcSEcCtD
Iloperidone—Dizziness—Epirubicin—pancreatic cancer	4.17e-05	0.000489	CcSEcCtD
Iloperidone—Diarrhoea—Doxorubicin—pancreatic cancer	3.99e-05	0.000468	CcSEcCtD
Iloperidone—Rash—Epirubicin—pancreatic cancer	3.98e-05	0.000466	CcSEcCtD
Iloperidone—Dermatitis—Epirubicin—pancreatic cancer	3.97e-05	0.000466	CcSEcCtD
Iloperidone—Dizziness—Doxorubicin—pancreatic cancer	3.86e-05	0.000452	CcSEcCtD
Iloperidone—Nausea—Epirubicin—pancreatic cancer	3.75e-05	0.000439	CcSEcCtD
Iloperidone—Rash—Doxorubicin—pancreatic cancer	3.68e-05	0.000431	CcSEcCtD
Iloperidone—Dermatitis—Doxorubicin—pancreatic cancer	3.68e-05	0.000431	CcSEcCtD
Iloperidone—Nausea—Doxorubicin—pancreatic cancer	3.47e-05	0.000406	CcSEcCtD
Iloperidone—HTR2A—Signaling by GPCR—PIK3CA—pancreatic cancer	2.81e-06	4.42e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—CCND1—pancreatic cancer	2.81e-06	4.41e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—CASP3—pancreatic cancer	2.81e-06	4.41e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—PIK3CA—pancreatic cancer	2.81e-06	4.41e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—KRAS—pancreatic cancer	2.81e-06	4.41e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—STAT3—pancreatic cancer	2.8e-06	4.39e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—CTNNB1—pancreatic cancer	2.8e-06	4.39e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—APOE—pancreatic cancer	2.8e-06	4.39e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—NRAS—pancreatic cancer	2.79e-06	4.38e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—KRAS—pancreatic cancer	2.79e-06	4.37e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—CTNNB1—pancreatic cancer	2.78e-06	4.37e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—GCG—pancreatic cancer	2.78e-06	4.36e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—PIK3CB—pancreatic cancer	2.77e-06	4.35e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—PIK3CA—pancreatic cancer	2.76e-06	4.32e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—MMP9—pancreatic cancer	2.74e-06	4.31e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—CCND1—pancreatic cancer	2.73e-06	4.29e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—MMP9—pancreatic cancer	2.73e-06	4.28e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—PTEN—pancreatic cancer	2.73e-06	4.28e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—PIK3CB—pancreatic cancer	2.73e-06	4.28e-05	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—PIK3CB—pancreatic cancer	2.72e-06	4.28e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—PIK3CB—pancreatic cancer	2.72e-06	4.27e-05	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—PIK3CB—pancreatic cancer	2.72e-06	4.27e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—PTEN—pancreatic cancer	2.71e-06	4.26e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—CTNNB1—pancreatic cancer	2.71e-06	4.25e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—KRAS—pancreatic cancer	2.71e-06	4.25e-05	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—PTGS2—pancreatic cancer	2.7e-06	4.24e-05	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—PTGS2—pancreatic cancer	2.69e-06	4.23e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—PIK3CB—pancreatic cancer	2.67e-06	4.19e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—CXCL8—pancreatic cancer	2.66e-06	4.18e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling by GPCR—AKT1—pancreatic cancer	2.66e-06	4.18e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—MMP9—pancreatic cancer	2.66e-06	4.17e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling by GPCR—AKT1—pancreatic cancer	2.65e-06	4.15e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling by GPCR—HRAS—pancreatic cancer	2.65e-06	4.15e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—PTEN—pancreatic cancer	2.64e-06	4.14e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—MYC—pancreatic cancer	2.64e-06	4.14e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—TGFB1—pancreatic cancer	2.63e-06	4.13e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—CXCL8—pancreatic cancer	2.62e-06	4.11e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—CXCL8—pancreatic cancer	2.62e-06	4.1e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—STK11—pancreatic cancer	2.61e-06	4.1e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling by GPCR—HRAS—pancreatic cancer	2.6e-06	4.09e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—MYC—pancreatic cancer	2.6e-06	4.08e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—PIK3CA—pancreatic cancer	2.6e-06	4.08e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—HRAS—pancreatic cancer	2.6e-06	4.08e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—PIK3CA—pancreatic cancer	2.6e-06	4.08e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—TGFB1—pancreatic cancer	2.59e-06	4.07e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—PIK3CA—pancreatic cancer	2.58e-06	4.05e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—EGFR—pancreatic cancer	2.58e-06	4.05e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling by GPCR—AKT1—pancreatic cancer	2.58e-06	4.04e-05	CbGpPWpGaD
Iloperidone—DRD2—GPCR downstream signaling—AKT1—pancreatic cancer	2.57e-06	4.04e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CXCL8—pancreatic cancer	2.57e-06	4.03e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—PTEN—pancreatic cancer	2.56e-06	4.02e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—PIK3CA—pancreatic cancer	2.56e-06	4.02e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—HRAS—pancreatic cancer	2.55e-06	4e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—CASP3—pancreatic cancer	2.55e-06	4e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—EGFR—pancreatic cancer	2.54e-06	3.99e-05	CbGpPWpGaD
Iloperidone—HTR2A—GPCR downstream signaling—AKT1—pancreatic cancer	2.53e-06	3.97e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—SRC—pancreatic cancer	2.53e-06	3.97e-05	CbGpPWpGaD
Iloperidone—HRH1—GPCR downstream signaling—AKT1—pancreatic cancer	2.53e-06	3.96e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	2.52e-06	3.96e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—SRC—pancreatic cancer	2.52e-06	3.95e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—TP53—pancreatic cancer	2.52e-06	3.95e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—TP53—pancreatic cancer	2.51e-06	3.94e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—CASP3—pancreatic cancer	2.51e-06	3.94e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—CASP3—pancreatic cancer	2.5e-06	3.93e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—TP53—pancreatic cancer	2.5e-06	3.92e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—PIK3CA—pancreatic cancer	2.49e-06	3.9e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—CCND1—pancreatic cancer	2.48e-06	3.89e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—PIK3CB—pancreatic cancer	2.48e-06	3.89e-05	CbGpPWpGaD
Iloperidone—ADRA1A—GPCR downstream signaling—AKT1—pancreatic cancer	2.48e-06	3.89e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—VEGFA—pancreatic cancer	2.46e-06	3.87e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—CTNNB1—pancreatic cancer	2.46e-06	3.86e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CASP3—pancreatic cancer	2.46e-06	3.85e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—VEGFA—pancreatic cancer	2.45e-06	3.85e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—SRC—pancreatic cancer	2.45e-06	3.84e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—CCND1—pancreatic cancer	2.44e-06	3.83e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—STAT3—pancreatic cancer	2.44e-06	3.83e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—CCND1—pancreatic cancer	2.44e-06	3.82e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—KRAS—pancreatic cancer	2.44e-06	3.82e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PPARG—pancreatic cancer	2.44e-06	3.82e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—NRAS—pancreatic cancer	2.43e-06	3.82e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—STAT3—pancreatic cancer	2.43e-06	3.81e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—NRAS—pancreatic cancer	2.42e-06	3.8e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—CTNNB1—pancreatic cancer	2.42e-06	3.79e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—CTNNB1—pancreatic cancer	2.41e-06	3.79e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—MMP9—pancreatic cancer	2.41e-06	3.78e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—HRAS—pancreatic cancer	2.41e-06	3.77e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—TP53—pancreatic cancer	2.4e-06	3.77e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—KRAS—pancreatic cancer	2.4e-06	3.77e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—HRAS—pancreatic cancer	2.4e-06	3.77e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—PTEN—pancreatic cancer	2.4e-06	3.76e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CCND1—pancreatic cancer	2.39e-06	3.75e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—HRAS—pancreatic cancer	2.39e-06	3.75e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CXCL8—pancreatic cancer	2.38e-06	3.74e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—VEGFA—pancreatic cancer	2.38e-06	3.74e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—MMP9—pancreatic cancer	2.37e-06	3.72e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—HRAS—pancreatic cancer	2.37e-06	3.72e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—APOE—pancreatic cancer	2.37e-06	3.72e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CTNNB1—pancreatic cancer	2.37e-06	3.72e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—MMP9—pancreatic cancer	2.37e-06	3.71e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—STAT3—pancreatic cancer	2.36e-06	3.7e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—PTEN—pancreatic cancer	2.36e-06	3.7e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—NRAS—pancreatic cancer	2.36e-06	3.7e-05	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—PTEN—pancreatic cancer	2.35e-06	3.69e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—PTEN—pancreatic cancer	2.35e-06	3.69e-05	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—PTEN—pancreatic cancer	2.35e-06	3.69e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling by GPCR—AKT1—pancreatic cancer	2.34e-06	3.67e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—MMP9—pancreatic cancer	2.32e-06	3.64e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—PTEN—pancreatic cancer	2.31e-06	3.62e-05	CbGpPWpGaD
Iloperidone—ADRA2A—GPCR downstream signaling—AKT1—pancreatic cancer	2.3e-06	3.61e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—HRAS—pancreatic cancer	2.3e-06	3.61e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling by GPCR—AKT1—pancreatic cancer	2.3e-06	3.61e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—AKT1—pancreatic cancer	2.29e-06	3.6e-05	CbGpPWpGaD
Iloperidone—CYP3A7—Metabolism—PIK3CA—pancreatic cancer	2.29e-06	3.6e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CASP3—pancreatic cancer	2.28e-06	3.58e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—MYC—pancreatic cancer	2.27e-06	3.56e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—TGFB1—pancreatic cancer	2.26e-06	3.55e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—MYC—pancreatic cancer	2.26e-06	3.54e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—AKT1—pancreatic cancer	2.25e-06	3.53e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—TGFB1—pancreatic cancer	2.25e-06	3.53e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—TYMS—pancreatic cancer	2.25e-06	3.53e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	2.24e-06	3.52e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—PIK3CA—pancreatic cancer	2.24e-06	3.51e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Metabolism—PIK3CA—pancreatic cancer	2.23e-06	3.49e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CCND1—pancreatic cancer	2.22e-06	3.49e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—SRC—pancreatic cancer	2.22e-06	3.49e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	2.22e-06	3.48e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—EGFR—pancreatic cancer	2.22e-06	3.48e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—PIK3CA—pancreatic cancer	2.21e-06	3.47e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—EGFR—pancreatic cancer	2.21e-06	3.46e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CTNNB1—pancreatic cancer	2.2e-06	3.45e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—MYC—pancreatic cancer	2.19e-06	3.44e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—TGFB1—pancreatic cancer	2.19e-06	3.43e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—SRC—pancreatic cancer	2.19e-06	3.43e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—SRC—pancreatic cancer	2.18e-06	3.42e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—TP53—pancreatic cancer	2.17e-06	3.4e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—VEGFA—pancreatic cancer	2.16e-06	3.39e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—MMP9—pancreatic cancer	2.16e-06	3.38e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—EGFR—pancreatic cancer	2.15e-06	3.37e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—PTEN—pancreatic cancer	2.14e-06	3.36e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—STAT3—pancreatic cancer	2.14e-06	3.36e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—SRC—pancreatic cancer	2.14e-06	3.36e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	2.14e-06	3.35e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—NRAS—pancreatic cancer	2.14e-06	3.35e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—TP53—pancreatic cancer	2.14e-06	3.35e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—VEGFA—pancreatic cancer	2.13e-06	3.34e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—VEGFA—pancreatic cancer	2.12e-06	3.33e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—AKT1—pancreatic cancer	2.12e-06	3.33e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—AKT1—pancreatic cancer	2.12e-06	3.33e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—AKT1—pancreatic cancer	2.11e-06	3.31e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—STAT3—pancreatic cancer	2.11e-06	3.31e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—STAT3—pancreatic cancer	2.1e-06	3.3e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—NRAS—pancreatic cancer	2.1e-06	3.3e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—NRAS—pancreatic cancer	2.1e-06	3.29e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—KRAS—pancreatic cancer	2.09e-06	3.29e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—AKT1—pancreatic cancer	2.09e-06	3.28e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—VEGFA—pancreatic cancer	2.08e-06	3.27e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—KRAS—pancreatic cancer	2.08e-06	3.27e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—HRAS—pancreatic cancer	2.07e-06	3.25e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—STAT3—pancreatic cancer	2.06e-06	3.24e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PPARG—pancreatic cancer	2.06e-06	3.24e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—NRAS—pancreatic cancer	2.06e-06	3.23e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—HRAS—pancreatic cancer	2.04e-06	3.21e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—AKT1—pancreatic cancer	2.03e-06	3.19e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—KRAS—pancreatic cancer	2.03e-06	3.18e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—MYC—pancreatic cancer	1.99e-06	3.12e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—SRC—pancreatic cancer	1.99e-06	3.12e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—TGFB1—pancreatic cancer	1.99e-06	3.12e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—MYC—pancreatic cancer	1.96e-06	3.07e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—MYC—pancreatic cancer	1.95e-06	3.07e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—TGFB1—pancreatic cancer	1.95e-06	3.07e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—TGFB1—pancreatic cancer	1.95e-06	3.06e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—EGFR—pancreatic cancer	1.95e-06	3.06e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—VEGFA—pancreatic cancer	1.94e-06	3.04e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	1.93e-06	3.03e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—PIK3CA—pancreatic cancer	1.92e-06	3.02e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—MYC—pancreatic cancer	1.92e-06	3.01e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—STAT3—pancreatic cancer	1.92e-06	3.01e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PTGS2—pancreatic cancer	1.92e-06	3.01e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—EGFR—pancreatic cancer	1.92e-06	3.01e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—PIK3CA—pancreatic cancer	1.91e-06	3e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—TGFB1—pancreatic cancer	1.91e-06	3e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—NRAS—pancreatic cancer	1.91e-06	3e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—EGFR—pancreatic cancer	1.91e-06	3e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	1.88e-06	2.95e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—EGFR—pancreatic cancer	1.88e-06	2.94e-05	CbGpPWpGaD
Iloperidone—CYP3A7—Metabolism—AKT1—pancreatic cancer	1.87e-06	2.94e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—PIK3CA—pancreatic cancer	1.86e-06	2.92e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—TP53—pancreatic cancer	1.86e-06	2.92e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—TP53—pancreatic cancer	1.85e-06	2.91e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—KRAS—pancreatic cancer	1.84e-06	2.89e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—AKT1—pancreatic cancer	1.83e-06	2.87e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—APOE—pancreatic cancer	1.83e-06	2.87e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Metabolism—AKT1—pancreatic cancer	1.82e-06	2.85e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—KRAS—pancreatic cancer	1.81e-06	2.84e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—PIK3CA—pancreatic cancer	1.81e-06	2.84e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—KRAS—pancreatic cancer	1.81e-06	2.83e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—AKT1—pancreatic cancer	1.8e-06	2.83e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—TP53—pancreatic cancer	1.8e-06	2.83e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—MYC—pancreatic cancer	1.78e-06	2.8e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—HRAS—pancreatic cancer	1.78e-06	2.79e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—TGFB1—pancreatic cancer	1.78e-06	2.79e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—KRAS—pancreatic cancer	1.77e-06	2.78e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—HRAS—pancreatic cancer	1.77e-06	2.78e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—EGFR—pancreatic cancer	1.74e-06	2.73e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—HRAS—pancreatic cancer	1.72e-06	2.7e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—PIK3CA—pancreatic cancer	1.69e-06	2.65e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PTEN—pancreatic cancer	1.67e-06	2.62e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—PIK3CA—pancreatic cancer	1.66e-06	2.61e-05	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—PIK3CA—pancreatic cancer	1.66e-06	2.61e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—PIK3CA—pancreatic cancer	1.66e-06	2.6e-05	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—PIK3CA—pancreatic cancer	1.66e-06	2.6e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	1.65e-06	2.59e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—KRAS—pancreatic cancer	1.65e-06	2.58e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	1.64e-06	2.57e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—TP53—pancreatic cancer	1.63e-06	2.57e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—PIK3CA—pancreatic cancer	1.63e-06	2.55e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PTGS2—pancreatic cancer	1.62e-06	2.55e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—TP53—pancreatic cancer	1.61e-06	2.52e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—TP53—pancreatic cancer	1.6e-06	2.52e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PPARG—pancreatic cancer	1.59e-06	2.5e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—TP53—pancreatic cancer	1.57e-06	2.47e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—AKT1—pancreatic cancer	1.57e-06	2.47e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—AKT1—pancreatic cancer	1.56e-06	2.45e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—HRAS—pancreatic cancer	1.56e-06	2.45e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—HRAS—pancreatic cancer	1.54e-06	2.41e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—HRAS—pancreatic cancer	1.53e-06	2.41e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—AKT1—pancreatic cancer	1.52e-06	2.39e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—PIK3CA—pancreatic cancer	1.51e-06	2.37e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—HRAS—pancreatic cancer	1.51e-06	2.36e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—AKT1—pancreatic cancer	1.48e-06	2.32e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—TP53—pancreatic cancer	1.46e-06	2.3e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	1.45e-06	2.28e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PTEN—pancreatic cancer	1.42e-06	2.22e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—HRAS—pancreatic cancer	1.4e-06	2.2e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—AKT1—pancreatic cancer	1.38e-06	2.17e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—AKT1—pancreatic cancer	1.36e-06	2.13e-05	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—AKT1—pancreatic cancer	1.36e-06	2.13e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—AKT1—pancreatic cancer	1.36e-06	2.13e-05	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—AKT1—pancreatic cancer	1.35e-06	2.13e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—AKT1—pancreatic cancer	1.33e-06	2.09e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	1.26e-06	1.98e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PTGS2—pancreatic cancer	1.25e-06	1.97e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—AKT1—pancreatic cancer	1.24e-06	1.94e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	1.18e-06	1.85e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PTEN—pancreatic cancer	1.09e-06	1.71e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	9.99e-07	1.57e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—AKT1—pancreatic cancer	9.63e-07	1.51e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—AKT1—pancreatic cancer	8.16e-07	1.28e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	7.71e-07	1.21e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—AKT1—pancreatic cancer	6.3e-07	9.88e-06	CbGpPWpGaD
